Jounce Therapeutics (NASDAQ: JNCE) reported Q4 EPS of ($0.29), $0.20 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $13 million versus the consensus estimate of $16.21 million.

Financial Guidance:

Based on its current plans, Jounce expects cash burn on operating expenses and capital expenditures for the full year 2018 to be approximately $80.0 million to $100.0 million. The Company expects to record approximately $50.0 million to $60.0 million in collaboration revenue in 2018 from the continued recognition of the Celgene upfront payment received in 2016.

Given the strength of its balance sheet, Jounce continues to expect its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements for at least the next 24 months

For earnings history and earnings-related data on Jounce Therapeutics (JNCE) click here.